Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

IMpower010: postoperative ctDNA positivity remained a poor prognostic factor at 5-year disease-free survival follow-up

At ESMO 2024, an updated IMpower010 analysis of resected stage II to IIIA non-small cell lung cancer reported that postoperative ctDNA positivity was a negative prognostic factor for disease-free survival after at least 5 years of follow-up, and that disease-free survival was longer with atezolizumab than with best supportive care in both ctDNA-positive and ctDNA-negative groups.

Annals of Oncology